Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent prior to initiation of any study mandated procedure~2. Patients with symptomatic PAH in World Health Organization (WHO) Functional Class (FC) II to IV~3. Patients with PAH belonging to one of the following subgroups of the Dana Point Clinical Classification Group 1:~   1. Idiopathic, or~  2. Heritable, or~  3. Drug or toxin induced, or~  4. Associated with one of the following:~   i. Connective tissue disease ii. Congenital heart disease with simple systemic-to-pulmonary shunt at least one year after surgical repair iii. HIV infection~4. Documented hemodynamic diagnosis of PAH by right heart catheterization - performed at any time prior to Screening showing:~   1. Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg and~  2. Resting pulmonary vascular resistance (PVR) \> 240 dyn•s•cm-5 and~  3. Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic pressure (LVEDP) ≤ 15 mmHg~5. 6-minute walk distance (6MWD) ≥ 150 m at Screening~6. Able to fluently speak and read English~7. For patients on phosphodiesterase type-5 inhibitors (PDE5i), inhaled prostacyclin analogues, or calcium channel blockers, stable doses for at least 3 months prior to Visit 2~8. For patients on oral diuretics, stable doses for at least 4 weeks prior to Visit 2~9. Men or women aged 18 or older~   1. A woman is considered to be of childbearing potential unless she:~      * Has not yet entered puberty, or~     * Does not have a uterus, or~     * Has gone through menopause (has not had a period for at least 12 months for natural reasons, or who has had their ovaries removed)~  2. A women of childbearing potential is eligible only if she meets both criteria below:~      * Has a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline and agree to perform monthly urine pregnancy tests, and~     * Agrees to use two methods of contraception (one method for patients with a progesterone implant or an intrauterine device or tubal sterilization) from the Screening Visit 1 until one month after study drug discontinuation~Exclusion Criteria:~1. Moderate to severe obstructive lung disease: forced expiratory volume in one second (FEV1) / forced vital capacity \< 70% and FEV1 \< 65% of predicted value after bronchodilator administration~2. Moderate to severe restrictive lung disease: total lung capacity \< 60% of predicted value~3. Hemoglobin \< 75% of the lower limit of the normal range at screening~4. Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 3 times the upper limit of normal (ULN) at screening~5. Estimated creatinine clearance \< 30 mL/min at screening~6. Systolic blood pressure (SBP) \< 90 mmHg at screening~7. Body weight \< 40 kg at screening~8. Known concomitant life-threatening diseases with a life expectancy of \< 12 months~9. Any condition that prevents compliance with the protocol or adherence to therapy~10. Treatment with endothelin receptor antagonists (ERAs) within 3 months prior to Visit 2, or scheduled to receive any of these compounds, other than macitentan, during the trial~11. Treatment with intravenous or subcutaneous prostacyclin or prostacyclin analogs within 3 months prior to Visit 2, or scheduled to receive any of these compounds during the trial~12. Treatment with riociguat within 3 months prior to Visit 2, or scheduled to receive riociguat during the trial~13. Treatment with strong cytochrome P450 (CYP) 3A4 inducers or inhibitors within 4 weeks prior to Visit 2~14. Recently started (\< 8 weeks prior to Visit 2) or planned cardio-pulmonary rehabilitation program based on exercise~15. Females who are lactating or pregnant (positive Screening or Baseline pregnancy test) or plan to become pregnant during the study~16. Known hypersensitivity to macitentan or its excipients or drugs of the same class~17. Treatment with another investigational drug within 3 months prior to Visit 2~18. Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Macitentan (Type: EXPERIMENTAL): Macitentan tablet, dose of 10 mg, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).